Sangamo Therapeutics Inc  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
+1.05 (12.88%)
After Hours: 9.40 +0.20 (2.17%)
Jun 22, 5:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.30 - 9.35
52 week 2.65 - 9.35
Open 8.35
Vol / Avg. 3.39M/2.40M
Mkt cap 657.80M
P/E     -
Div/yield     -
EPS -1.02
Shares 71.94M
Beta 3.37
Inst. own 59%
Aug 1, 2017
Q2 2017 Sangamo Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 14, 2017
Sangamo Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2017
Sangamo Therapeutics Inc at Jefferies Healthcare Conference
Jun 5, 2017
Sangamo Therapeutics Inc Annual Shareholders Meeting
May 10, 2017
Q1 2017 Sangamo Therapeutics Inc Earnings Call
May 10, 2017
Q1 2017 Sangamo Therapeutics Inc Earnings Release
Apr 27, 2017
Sangamo Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -485.61% -369.58%
Operating margin -490.28% -374.23%
EBITD margin - -369.07%
Return on average assets -43.79% -38.20%
Return on average equity -50.95% -43.61%
Employees 131 -
CDP Score - -


501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Officers and directors

Alexander Macrae President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Kathy Yi Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 59
Bio & Compensation  - Reuters
William R. Ringo Jr. Director
Age: 71
Bio & Compensation  - Reuters
Stephen G. Dilly M.D. Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 81
Bio & Compensation  - Reuters
Steven J. Mento Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters